Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of Anti-C5aR Antibody NNC 0151-0000-0000 in Healthy Subjects
NCT02151409Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of neutrazumab in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Adverse events. Started Jun 2008; status: completed.
02
Drugs
neutrazumab
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02151409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151409.